- Home
- Companies
- usa north carolina
- clinical program
Refine by
Clinical Program Suppliers Serving Usa North Carolina
12 companies found
Technologybased inRye Brook, NEW YORK (USA)
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is ...
Technologybased inBoston, MASSACHUSETTS (USA)
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — ...
Technologybased inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of ...
Technologybased inSan Diego, CALIFORNIA (USA)
Resilience is your biomanufacturing innovation partner, leading the pursuit of novel medicines by revolutionizing how they’re made, funded and scaled. The technology of manufacturing complex medicines, like cell and gene therapies, hasn’t kept pace ...
As recombinant protein and monoclonal antibody treatments continue to provide promising pathways for both existing indications and new ones, Resilience has the clinical and commercial experience, expertise and capacity to be your preferred ...
Technologybased inWhite Plains, NEW YORK (USA)
Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy ...
While Alzheimer’s is the largest tauopathy, other tauopathies are rare diseases that present accelerated regulatory pathways and significant near-term commercial opportunities. These rare diseases shown in Chart A below have a tau etiology ...
Technologybased inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Technologybased inOrleans,, ONTARIO (CANADA)
Tetra Bio-Pharma is focused on providing clinical programs aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma is specialized in combining the traditional methods of medicinal cannabis use with ...
Technologybased inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
GW is committed to developing new medicines to treat rare, treatment-resistant epilepsy conditions where there are limited or in some cases, no approved treatment ...
Technologybased inCoral Gables, FLORIDA (USA)
We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their ...
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major ...
Technologybased inParamus, NEW JERSEY (USA)
Starton is an emerging clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Focused on continuous ...
STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is in development for new multiple myeloma indications for lenalidomide and achievement of superiority versus oral lenalidomide in maintenance ...
Technologybased inRoden, NETHERLANDS
Pure Inhalation Medication Systems (PureIMS) is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops. The focus is on the treatment of ...